Association between the difference in estimated GFR based on cystatin C versus creatinine in coronary artery diseases

冠状动脉疾病中基于胱抑素C与肌酐估算的肾小球滤过率差异与冠状动脉疾病之间的关联

阅读:1

Abstract

BACKGROUND: The difference in estimated glomerular filtration rate (eGFR) derived from creatinine and cystatin C (eGFR(diff)) has been noticed recently and the relationship with poor cardiovascular prognosis has been proven. However, primary prevention of the risk of coronary artery disease (CAD) is equally important but there is a lack of studies specifically investigating this implication. METHODS: This prospective cohort study utilized data from the UK Biobank, including 437,536 participants without CAD at baseline. The primary outcome was defined as CAD. The eGFR(diff) was calculated by subtracting creatinine-based eGFR from cystatin C-based eGFR. Participants were then categorized into a negative, intermediate range, and positive group based on thresholds of -15 mL/min/1.73 m(2) and 15 mL/min/1.73 m(2). Cox proportional risk models were used to evaluate the associations of eGFR(diff) with CAD and the relationship among different genetic risks of CAD. RESULTS: During a median follow-up of 13.8 years, CAD occurred in 36,797 participants. In the fully adjusted model, compared to midrange eGFR(diff,) participants with a positive eGFR(diff) had a lower risk of CAD (HR 0.717, 95%CI 0.675-0.762), while with a negative eGFR(diff) had a higher risk (HR 1.433, 95%CI 1.399-1.468). When eGFR(diff) was treated as a continuous variable, a statistically significant trend toward a lower risk of CAD as eGFR(diff) increased (HR 0.982, 95% CI 0.981-0.982). Moreover, this relationship is independent of genetic susceptibility. CONCLUSIONS: eGFR(diff) was associated with CAD risk, where a high eGFR(diff) corresponded to a decreased likelihood of CAD onset no matter genetic susceptibility.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。